Related Experiment Video

Updated: Aug 10, 2026

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

[Chronic renal failure and growth hormone: effects on GH-IGF axis and leptin]

Josenilson C de Oliveira1, Francisco de A Machado Neto, André Moreno Morcillo

  • 1Laboratório de Crescimento e Composição Corporal, Centro de Investigação em Pediatria, FCM-UNICAMP, Campinas, SP.

Arquivos Brasileiros De Endocrinologia E Metabologia
|March 18, 2006
PubMed

Insights

Recombinant human growth hormone (rhGH) therapy in short children with chronic renal failure (CRF) significantly increased Insulin-like Growth Factor-1 (IGF-1) and IGF Binding Protein-3 (IGFBP-3). Leptin and insulin levels remained stable, indicating insulin resistance.

Area of Science:

  • Pediatric Endocrinology
  • Nephrology
  • Metabolic Research

Context:

  • Short stature in children with chronic renal failure (CRF) presents significant growth challenges.
  • Recombinant human growth hormone (rhGH) is a potential therapeutic option for growth promotion.
  • Understanding the metabolic effects of rhGH in this population is crucial.

Purpose:

  • To investigate the impact of rhGH replacement therapy on key metabolic markers.
  • To analyze changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Protein-3 (IGFBP-3), leptin, and insulin levels.
  • To assess the association between rhGH treatment and insulin resistance in prepubertal children with CRF.

Summary:

  • Eleven short prepubertal children with CRF received rhGH (0.23 mg/Kg weekly) for 12 months.
  • Serum levels of IGF-1 and IGFBP-3 showed a significant increase post-treatment.
  • Leptin, glucose, and insulin levels did not significantly change, with observed normal leptin/glucose and high insulin.

Impact:

  • rhGH therapy effectively enhances IGF-1 and IGFBP-3 levels in children with CRF.
  • The treatment appears to be associated with a state of insulin resistance.
  • These findings contribute to optimizing growth hormone therapy strategies in pediatric nephrology.
Abstract

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...